Utilization of TAS-102 (TAS) or Regorefenib (rego) among Commercially Insured Refractory Metastatic Colorectal Cancer (R-Mcrc) Patients.
JOURNAL OF CLINICAL ONCOLOGY(2024)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
JOURNAL OF CLINICAL ONCOLOGY(2024)